This inventor holds 1 USPTO granted patent. Top assignee: Equispharm Co., Ltd. Active years: 2006.
Company Filing History:
Years Active: 2006
Title: The Innovations of Seung-Moak Kim
Introduction
Seung-Moak Kim is a prominent inventor based in Daejeon-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications in cancer treatment and inflammatory diseases.
Latest Patents
One of his notable patents is related to fumagillol derivatives and their preparation methods. This patent describes a fumagillol compound that serves as an angiogenesis inhibiting agent, demonstrating a superior angiogenesis inhibitory effect with reduced toxicity. Additionally, it has potential applications as a cancer metastasis inhibitor and a therapeutic agent for various inflammatory diseases, including rheumatic disease, psoriasis, and diabetic retinopathy.
Career Highlights
Seung-Moak Kim is associated with Equispharm Co., Ltd., where he continues to innovate and develop new therapeutic solutions. His work has garnered attention for its potential impact on cancer treatment and the management of inflammatory conditions.
Collaborations
He collaborates with notable colleagues such as Cheol-Kyu Han and Jeong-Hyeok Yoon, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Seung-Moak Kim's contributions to the field of pharmaceuticals highlight the importance of innovation in developing effective treatments for serious health conditions. His work exemplifies the potential of scientific research to improve patient outcomes and advance medical knowledge.